AI Summary
The article discusses the results of a phase 2 trial (MOLTO) on combining atezolizumab, venetoclax, and obinutuzumab in treating Richter transformation diffuse large B-cell lymphoma (DLBCL-RT). The study indicates that this chemotherapy-free regimen is effective and safe, potentially offering a new first-line treatment option for patients with DLBCL-RT.
The atezolizumab, venetoclax, and obinutuzumab triplet combination was shown to be active and safe, suggesting that this chemotherapy-free regimen could become a new first-line treatment approach in patients with DLBCL-RT.